Rexahn Pharmaceuticals (REXN) Short Interest Ratio & Short Volume

Short interest is the volume of Rexahn Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 46,100 shares of REXN short. Learn More on Rexahn Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. REXN shares currently have a short interest ratio of 1.0. Learn More on Rexahn Pharmaceuticals's short interest ratio.

Rexahn Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 46,100 shares, an increase of 109.5% from the previous total of 22,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Rexahn Pharmaceuticals: LAVA Therapeutics (0.88%), Cadrenal Therapeutics, Inc. (2.45%), Kezar Life Sciences, Inc. (1.09%), Marinus Pharmaceuticals, Inc. (3.95%), Allakos Inc. (1.36%), FibroGen, Inc. (4.23%), CalciMedica, Inc. (1.75%), Protagenic Therapeutics, Inc. (4.53%), ALX Oncology Holdings Inc. (18.06%), Daré Bioscience, Inc. (0.54%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($6.95 billion), Aon plc ($4.44 billion), Analog Devices, Inc. ($4.13 billion), Snap Inc. ($3.12 billion), Peloton Interactive, Inc. ($2.62 billion), Moderna, Inc. ($2.60 billion), The Clorox Company ($2.47 billion), The Kroger Co. ($2.32 billion), International Flavors & Fragrances Inc. ($2.21 billion), and Altice USA, Inc. ($1.94 billion). View all of the most shorted stocks.

Short selling REXN is an investing strategy that aims to generate trading profit from Rexahn Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Rexahn Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of REXN, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including REXN, twice per month. The most recent reporting period available is December, 31 2020.